For research use only. Not for therapeutic Use.
EIDD-2749 (4′-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses[1][2][3].
EIDD-2749 induces a delayed stalling of phosphodiester bond formation by RSV and SARS-CoV-2 RdRP[1].
EIDD-2749 is rapidly anabolizes, metabolically stable, and potently antiviral in disease-relevant well-differentiated HAE cultures[1].
EIDD-2749 shows a ≥17-fold increase in anti-RSV potency relative to that on HEp-2 cells; however, the low cytotoxicity levels remains unchanged (CC50 169 mM), resulting in a high SI (SI = EC50/CC50) of ≥1877[1].
EIDD-2749 inhibits SARS-CoV-2 with an EC50 value of 0.2-0.6 M[2].
EIDD-2749 has an EC50 of 1.86 μM in theVero E6 cell line, cytotoxicity with a CC50 of 380 μM, and stability in human plasma[3].
EIDD-2749 (0.2, 1, 5 mg/kg; p.o.; single daily for 4 days) shows good orally efficacious in RSV infection mice model in a dose-dependent manner[1].
EIDD-2749 shows high efficacious to SARS-CoV-2 infection and is effective with a single daily dose versus molnupiravir administered twice daily in vivo[2].
| Catalog Number | I042652 |
| CAS Number | 1613589-24-4 |
| Synonyms | 1-[(2R,3S,5S)-5-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione |
| Molecular Formula | C9H11FN2O6 |
| Purity | ≥95% |
| InChI | InChI=1S/C9H11FN2O6/c10-9(3-13)6(16)5(15)7(18-9)12-2-1-4(14)11-8(12)17/h1-2,5-7,13,15-16H,3H2,(H,11,14,17)/t5-,6?,7+,9+/m0/s1 |
| InChIKey | RDCYLPRXPILMRP-YUOMSVSZSA-N |
| SMILES | C1=CN(C(=O)NC1=O)C2C(C(C(O2)(CO)F)O)O |
| Reference | [1]. Sourimant J, et al. 4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science. 2022 Jan 14;375(6577):161-167. [2]. Abas AH, et al. 4’-fluorouridine and its derivatives as potential COVID-19 oral drugs: a review [version 1; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2022, 11:410. [3]. George R. Painter, et al. 4′-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. Patent WO2019173602A1. |
